Stockreport

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)

STEMLINE THERAPEUTICS  (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
PDF NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercial [Read more]